SIRPA and myelodysplastic syndrome: Moreover, regimens using naked antibodies, which avoid the potential toxicities of ADC payloads, have been described in which targeting CD117 alone or in combination with blockade of the CD47/SIRPα axis successfully permitted disease correction in mouse models of chronic granulomatous disease (10) and myelodysplastic syndrome (MDS) (11).